Predictmedix AI Inc (CSE:PMED) (OTC:PMEDF) (FRA:3QP), a developer of artificial intelligence-driven health screening solutions, on Wednesday announced the launch of a mobile, AI-powered diabetes screening platform, marking its entry into the direct-to-consumer health diagnostics market.

The solution leverages facial and biometric analysis to deliver instant diabetic risk assessments via smartphone, removing the need for blood draws or clinical visits.

India will serve as the launch market, targeting over 100 million individuals living with diabetes, many of whom remain undiagnosed.

The platform aims to expand access to preventive healthcare across underserved populations through affordable and scalable screening. It features multilingual support, user-friendly design, and complies with India's Digital Personal Data Protection Act.

This initiative aligns with Predictmedix AI's strategy to drive mass adoption of non-invasive, AI-enabled health screening globally.

According to the company, the technology empowers users to manage their health using their existing mobile devices.